Feeds › Ownership stakes (13D / 13G)
Ownership stakes (13D / 13G)
Investors who own more than 5% of a company, from activists (13D) to passive holders (13G).
About this data
- What it is
- An investor who owns more than 5% of a public company must say so. Investors who may try to influence the company, such as activists, file the longer Schedule 13D; passive holders file the shorter Schedule 13G.
- Who files it
- The investor, within days of crossing 5%, and again whenever the stake changes materially.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- 13G filings are far more common than 13D. A 13D usually means the investor intends to push for changes, so it tends to get more attention.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Filings per day, last 30 days
13D (activist) 13G (passive)
Latest ownership filings
Showing: ticker ODTX
| Filed | ScheduleBoth report a stake of more than 5%. A 13D is filed by investors who may try to influence the company, such as activists; a 13G by passive holders. | Company | Investor | Shares | % of shares | Filing |
|---|---|---|---|---|---|---|
| Nov 5, 2026 | SCHEDULE 13G/A (amended) | ODTX Odyssey Therapeutics, Inc. | Abigail P. Johnson | 6.24M | 13.0% | SCHEDULE 13G/A ↗ |
| Nov 5, 2026 | SCHEDULE 13G/A (amended) | ODTX Odyssey Therapeutics, Inc. | FMR LLC | 6.24M | 13.0% | SCHEDULE 13G/A ↗ |
| Jun 5, 2026 | SCHEDULE 13G | ODTX Odyssey Therapeutics, Inc. | Abigail P. Johnson | 4.58M | 10.2% | SCHEDULE 13G ↗ |
| Jun 5, 2026 | SCHEDULE 13G | ODTX Odyssey Therapeutics, Inc. | FMR LLC | 4.58M | 10.2% | SCHEDULE 13G ↗ |
| May 18, 2026 | SCHEDULE 13G | ODTX Odyssey Therapeutics, Inc. | Lightspeed Ultimate General Partner XV-B (Ignite), L.L.C. | 3.61M | 7.6% | SCHEDULE 13G ↗ |
| May 18, 2026 | SCHEDULE 13G | ODTX Odyssey Therapeutics, Inc. | Lightspeed General Partner XV-B (Ignite), L.P. | 3.61M | 7.6% | SCHEDULE 13G ↗ |
| May 18, 2026 | SCHEDULE 13G | ODTX Odyssey Therapeutics, Inc. | Lightspeed Venture Partners XV-B (Ignite), L.P. | 3.61M | 7.6% | SCHEDULE 13G ↗ |
| May 18, 2026 | SCHEDULE 13D | ODTX Odyssey Therapeutics, Inc. | Jon Winkelried | 3.69M | 7.8% | SCHEDULE 13D ↗ |
| May 18, 2026 | SCHEDULE 13D | ODTX Odyssey Therapeutics, Inc. | James G. Coulter | 3.69M | 7.8% | SCHEDULE 13D ↗ |
| May 18, 2026 | SCHEDULE 13D | ODTX Odyssey Therapeutics, Inc. | TPG GP A, LLC | 3.69M | 7.8% | SCHEDULE 13D ↗ |
| May 18, 2026 | SCHEDULE 13D | ODTX Odyssey Therapeutics, Inc. | George Simeon | 3.79M | 8.0% | SCHEDULE 13D ↗ |
| May 18, 2026 | SCHEDULE 13D | ODTX Odyssey Therapeutics, Inc. | SR One Capital SMA Partners, LP | 1.01M | 2.2% | SCHEDULE 13D ↗ |
| May 18, 2026 | SCHEDULE 13D | ODTX Odyssey Therapeutics, Inc. | Amzl, LP | 1.01M | 2.2% | SCHEDULE 13D ↗ |
| May 18, 2026 | SCHEDULE 13D | ODTX Odyssey Therapeutics, Inc. | SR One Co-Invest IV Manager, LLC | 948,649 | 2.0% | SCHEDULE 13D ↗ |
| May 18, 2026 | SCHEDULE 13D | ODTX Odyssey Therapeutics, Inc. | SR One Co-Invest IV-A, LLC | 574,314 | 1.2% | SCHEDULE 13D ↗ |
| May 18, 2026 | SCHEDULE 13D | ODTX Odyssey Therapeutics, Inc. | SR One Co-Invest IV, LLC | 374,335 | 0.8% | SCHEDULE 13D ↗ |
| May 18, 2026 | SCHEDULE 13D | ODTX Odyssey Therapeutics, Inc. | SR One Capital Partners I, LP | 1.83M | 3.9% | SCHEDULE 13D ↗ |
| May 18, 2026 | SCHEDULE 13D | ODTX Odyssey Therapeutics, Inc. | SR One Capital Fund I Aggregator, LP | 1.83M | 3.9% | SCHEDULE 13D ↗ |
| May 18, 2026 | SCHEDULE 13D | ODTX Odyssey Therapeutics, Inc. | SR One Capital Management, LLC | 3.79M | 8.0% | SCHEDULE 13D ↗ |
| May 15, 2026 | SCHEDULE 13D | ODTX Odyssey Therapeutics, Inc. | Nan Li | 3.33M | 7.1% | SCHEDULE 13D ↗ |
| May 15, 2026 | SCHEDULE 13D | ODTX Odyssey Therapeutics, Inc. | Zavain Dar | 3.33M | 7.1% | SCHEDULE 13D ↗ |
| May 15, 2026 | SCHEDULE 13D | ODTX Odyssey Therapeutics, Inc. | Adam Goulburn | 3.33M | 7.1% | SCHEDULE 13D ↗ |
| May 15, 2026 | SCHEDULE 13D | ODTX Odyssey Therapeutics, Inc. | Dimension Management GP, LLC | 3.33M | 7.1% | SCHEDULE 13D ↗ |
| May 15, 2026 | SCHEDULE 13D | ODTX Odyssey Therapeutics, Inc. | Dimension Capital II GP, LLC | 3.33M | 7.1% | SCHEDULE 13D ↗ |
| May 15, 2026 | SCHEDULE 13D | ODTX Odyssey Therapeutics, Inc. | Dimension Capital II, L.P. | 3.33M | 7.1% | SCHEDULE 13D ↗ |
| May 15, 2026 | SCHEDULE 13D | ODTX Odyssey Therapeutics, Inc. | Dimension Management, L.P. | 3.33M | 7.1% | SCHEDULE 13D ↗ |
| May 15, 2026 | SCHEDULE 13D | ODTX Odyssey Therapeutics, Inc. | Sabine Dandiguian | 3.69M | 7.8% | SCHEDULE 13D ↗ |
| May 15, 2026 | SCHEDULE 13D | ODTX Odyssey Therapeutics, Inc. | Rafaele Tordjman | 3.69M | 7.8% | SCHEDULE 13D ↗ |
| May 15, 2026 | SCHEDULE 13D | ODTX Odyssey Therapeutics, Inc. | Jeito Capital SAS | 3.69M | 7.8% | SCHEDULE 13D ↗ |
| May 15, 2026 | SCHEDULE 13D | ODTX Odyssey Therapeutics, Inc. | Jeito II S.L.P. | 3.69M | 7.8% | SCHEDULE 13D ↗ |
30 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 7:26 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances